Together with previous work, our study highlights ARHGAP42 and uc010rul as novel targets for NPC therapy that may facilitate future nasopharyngeal carcinoma diagnosis and targeted therapy research. Here, ARHGAP42 is linked to nasopharyngeal carcinoma.